Human physiomimetic model integrating microphysiological systems of the gut, liver, and brain for studies of neurodegenerative diseases

作者：M. Trapecar, E. Wogram, Devon S. Svoboda, C. Communal, Attya Omer, T. Lungjangwa, Pierre Sphabmixay, J. Velazquez, Kirsten Schneider, C. Wright, Samuel Mildrum, Austin Hendricks, S. Levine, J. Muffat, Meelim J. Lee, D. Lauffenburger, D. Trumper, R. Jaenisch, L. Griffith · 发表于：Science Advances · 年份：2021 · DOI：10.1126/sciadv.abd1707 · 被引用次数：149 · 研究领域：Medicine

Engineered model of the human gut-liver-brain axis can be used to study the link between the microbiome and Parkinson’s disease. Slow progress in the fight against neurodegenerative diseases (NDs) motivates an urgent need for highly controlled in vitro systems to investigate organ-organ– and organ-immune–specific interactions relevant for disease pathophysiology. Of particular interest is the gut/microbiome-liver-brain axis for parsing out how genetic and environmental factors contribute to NDs. We have developed a mesofluidic platform technology to study gut-liver-cerebral interactions in the context of Parkinson’s disease (PD). It connects microphysiological systems (MPSs) of the primary human gut and liver with a human induced pluripotent stem cell–derived cerebral MPS in a systemically circulated common culture medium containing CD4+ regulatory T and T helper 17 cells. We demonstrate this approach using a patient-derived cerebral MPS carrying the PD-causing A53T mutation, gaining two important findings: (i) that systemic interaction enhances features of in vivo–like behavior of cerebral MPSs, and (ii) that microbiome-associated short-chain fatty acids increase expression of pathology-associated pathways in PD.